ST3GAL5 antibody (N-Term)
Quick Overview for ST3GAL5 antibody (N-Term) (ABIN630451)
Target
See all ST3GAL5 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Specificity
- ST3 GAL5 antibody was raised against the N terminal of ST3 AL5
-
Purification
- Purified
-
Immunogen
- ST3 GAL5 antibody was raised using the N terminal of ST3 AL5 corresponding to a region with amino acids DSEAESKYDPPFGFRKFSSKVQTLLELLPEHDLPEHLKAKTCRRCVVIGS
-
-
-
-
Application Notes
-
WB: 1.25 µg/mL, IHC: 4-8 µg/mL
Optimal conditions should be determined by the investigator. -
Comment
-
ST3GAL5 Blocking Peptide, (ABIN937546), is also available for use as a blocking control in assays to test for specificity of this ST3GAL5 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of ST0 AL5 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Handling Advice
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- ST3GAL5 (ST3 beta-Galactoside alpha-2,3-Sialyltransferase 5 (ST3GAL5))
-
Alternative Name
- ST3GAL5
-
Background
- Ganglioside GM3 is known to participate in the induction of cell differentiation, modulation of cell proliferation, maintenance of fibroblast morphology, signal transduction, and integrin-mediated cell adhesion. ST3GAL5 is a type II membrane protein which catalyzes the formation of GM3 using lactosylceramide as the substrate. It is a member of glycosyltransferase family 29 and may be localized to the Golgi apparatus. Mutation in its gene has been associated with Amish infantile epilepsy syndrome.
-
Molecular Weight
- 48 kDa (MW of target protein)
Target
-